We noticed you’re blocking ads

Thanks for visiting MillennialEYE. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.

In order to avoid adverse performance issues with this site, please white list https://millennialeye.com in your ad blocker then refresh this page.

Need help? Click here for instructions.

Digital Outsert | Sept/Oct '20

Break Free From Tradition with the AcrySof IQ PanOptix Trifocal IOL – William F. Wiley, MD

William F. Wiley, MD, has a wide range of hobbies, including surfing and fly fishing. As such, he understands that he’d be hindered when trying to enjoy these activities if he had to wear contact lenses or glasses—and the same goes for his patients. It’s this understanding and consideration for his patients’ visual needs that led Dr. Wiley to the Alcon AcrySof IQ PanOptix Trifocal IOL.

We all want freedom to pursue the activities we enjoy. Whether it’s for play or competition, our vision is paramount.

“I have to have confidence that I can deliver the outcomes my patients are looking for. PanOptix gives me that confidence.”

William F. Wiley, MD on Breaking Free:

Bill Wiley, MD, recognizes that if he had to wear contacts or glasses while trying to enjoy his own hobbies, he would be hindered. So, why expect that from his patients? With the AcrySof IQ PanOptix Trifocal IOL by Alcon, Dr. Wiley has broken free from tradition to offer full-vision function to his patients.

In today’s world we dive deep into our hobbies. We’re well-versed in the technicalities, and we want to invest in the equipment necessary to get to that next level.

“As a provider, I think it’s essential to identify with patients and understand how they’re going to use their vision. I want to understand my patients’ goals and help them to achieve them.”

How your IOL performs in low light matters.

“We often take for granted how we use our vision, and losing our full range of vision can be limiting. That is simply not something I have to worry about with the PanOptix lens.”

More surgeons on breaking free:

*Based on mean value of binocular defocus curve at near, intermediate and distance at 6 months (n=127).

†Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 ETDRS chart letters in the line were identified correctly.

1. AcrySof® IQ PanOptix® Directions for Use.

US-ACP-2000184

© 2020 Alcon Inc. 09/20

PanOptix is a trademark of Alcon. All other brand/product names are the trademarks of their respective owners.

AcrySof® IQ PanOptix® Family of Trifocal IOLs

IMPORTANT PRODUCT INFORMATION

CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician.

INDICATIONS: The AcrySof® IQ PanOptix® Trifocal IOLs include AcrySof® IQ PanOptix® and AcrySof® IQ PanOptix® Toric and are indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients, with less than 1 diopter of pre-existing corneal astigmatism, in whom a cataractous lens has been removed. The lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity, while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. In addition, the AcrySof® IQ PanOptix® Toric Trifocal IOL is indicated for the reduction of residual refractive astigmatism.

WARNINGS/PRECAUTIONS: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia and ensure that IOL centration is achieved.

For the AcrySof® IQ PanOptix® Toric Trifocal IOL, the lens should not be implanted if the posterior capsule is ruptured, if the zonules are damaged or if a primary posterior capsulotomy is planned. Rotation can reduce astigmatic correction. If necessary, lens repositioning should occur as early as possible prior to lens encapsulation.

Some visual effects may be expected due to the superposition of focused and unfocused multiple images. These may include some perceptions of halos or starbursts, as well as other visual symptoms. As with other multifocal IOLs, there is a possibility that visual symptoms may be significant enough that the patient will request explant of the multifocal IOL. A reduction in contrast sensitivity as compared to a monofocal IOL may be experienced by some patients and may be more prevalent in low lighting conditions. Therefore, patients implanted with multifocal IOLs should exercise caution when driving at night or in poor visibility conditions.

Patients should be advised that unexpected outcomes could lead to continued spectacle dependence or the need for secondary surgical intervention (e.g., intraocular lens replacement or repositioning).

As with other multifocal IOLs, patients may need glasses when reading small print or looking at small objects. Posterior capsule opacification (PCO) may significantly affect the vision of patients with multifocal IOLs sooner in its progression than patients with monofocal IOLs. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure, available from Alcon, informing them of possible risks and benefits associated with the AcrySof® IQ PanOptix® Trifocal IOLs.

ATTENTION: Reference the Directions for Use labeling for each IOL for a complete listing of indications, warnings and precautions.

Advertisement - Issue Continues Below
Publication Ad Publication Ad
End of Advertisement - Issue Continues Below